Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk

J. E. Goodman, J. A. Lavigne, J. G. Hengstler, B. Tanner, K. J. Helzlsouer, James D Yager

Research output: Contribution to journalArticle

Abstract

A valine-108-methionine polymorphism in exon 4 of the catechol-O-methyltransferase (COMT) gene muses a 3- to 4-fold reduction in enzyme activity and has been associated with an increased risk of breast cancer. This increased risk may be attributable to a decreased ability of the protein encoded by the low-activity allele (COMTL) to methylate and inactivate catechol estrogens, which have been implicated in estrogen carcinogenesis. Because estrogens have also been implicated in the etiology of ovarian cancer, we analyzed 108 cases and 106 controls from a case-control study conducted in Mainz, Germany, to test the hypothesis that COMTL is associated with ovarian cancer risk. No significant association was found between the COMT genotype and ovarian cancer risk (for the intermediate-activity COMT genotype versus the high-activity COMT genotype, OR, 1.29; 95% CI, 0.63-2.64; for the low-activity COMT genotype versus the high-activity COMT genotype, OR, 1.17; 95% CI, 0.52-2.61). We also hypothesized that women who were both low-activity COMT genotype- and glutathione S-transferase (CST) M1- and/or T1 null would be at higher risk for ovarian cancer because the combination of these genotypes could theoretically lead to higher catechol estrogen exposure. However, the association between the COMT polymorphism and ovarian cancer risk was similar across GSTM1 and GSTT1 genotypes (Ptrend > 0.40, for all strata). Because of the small sample size of this study population, odds ratios of a small magnitude could not be completely ruled out; however, the results presented do not support a strong association between the COMT polymorphism and the risk of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1373-1376
Number of pages4
JournalCancer Epidemiology Biomarkers and Prevention
Volume9
Issue number12
StatePublished - 2000

Fingerprint

Catechol O-Methyltransferase
Ovarian Neoplasms
Genotype
Catechol Estrogens
Estrogens
Alprostadil
Valine
Methionine
Sample Size
Germany
Case-Control Studies
Exons
Carcinogenesis
Alleles
Odds Ratio
Breast Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Goodman, J. E., Lavigne, J. A., Hengstler, J. G., Tanner, B., Helzlsouer, K. J., & Yager, J. D. (2000). Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk. Cancer Epidemiology Biomarkers and Prevention, 9(12), 1373-1376.

Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk. / Goodman, J. E.; Lavigne, J. A.; Hengstler, J. G.; Tanner, B.; Helzlsouer, K. J.; Yager, James D.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 9, No. 12, 2000, p. 1373-1376.

Research output: Contribution to journalArticle

Goodman, JE, Lavigne, JA, Hengstler, JG, Tanner, B, Helzlsouer, KJ & Yager, JD 2000, 'Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk', Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 12, pp. 1373-1376.
Goodman, J. E. ; Lavigne, J. A. ; Hengstler, J. G. ; Tanner, B. ; Helzlsouer, K. J. ; Yager, James D. / Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk. In: Cancer Epidemiology Biomarkers and Prevention. 2000 ; Vol. 9, No. 12. pp. 1373-1376.
@article{313598a3f3354350a7cfad111aedd67b,
title = "Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk",
abstract = "A valine-108-methionine polymorphism in exon 4 of the catechol-O-methyltransferase (COMT) gene muses a 3- to 4-fold reduction in enzyme activity and has been associated with an increased risk of breast cancer. This increased risk may be attributable to a decreased ability of the protein encoded by the low-activity allele (COMTL) to methylate and inactivate catechol estrogens, which have been implicated in estrogen carcinogenesis. Because estrogens have also been implicated in the etiology of ovarian cancer, we analyzed 108 cases and 106 controls from a case-control study conducted in Mainz, Germany, to test the hypothesis that COMTL is associated with ovarian cancer risk. No significant association was found between the COMT genotype and ovarian cancer risk (for the intermediate-activity COMT genotype versus the high-activity COMT genotype, OR, 1.29; 95{\%} CI, 0.63-2.64; for the low-activity COMT genotype versus the high-activity COMT genotype, OR, 1.17; 95{\%} CI, 0.52-2.61). We also hypothesized that women who were both low-activity COMT genotype- and glutathione S-transferase (CST) M1- and/or T1 null would be at higher risk for ovarian cancer because the combination of these genotypes could theoretically lead to higher catechol estrogen exposure. However, the association between the COMT polymorphism and ovarian cancer risk was similar across GSTM1 and GSTT1 genotypes (Ptrend > 0.40, for all strata). Because of the small sample size of this study population, odds ratios of a small magnitude could not be completely ruled out; however, the results presented do not support a strong association between the COMT polymorphism and the risk of ovarian cancer.",
author = "Goodman, {J. E.} and Lavigne, {J. A.} and Hengstler, {J. G.} and B. Tanner and Helzlsouer, {K. J.} and Yager, {James D}",
year = "2000",
language = "English (US)",
volume = "9",
pages = "1373--1376",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk

AU - Goodman, J. E.

AU - Lavigne, J. A.

AU - Hengstler, J. G.

AU - Tanner, B.

AU - Helzlsouer, K. J.

AU - Yager, James D

PY - 2000

Y1 - 2000

N2 - A valine-108-methionine polymorphism in exon 4 of the catechol-O-methyltransferase (COMT) gene muses a 3- to 4-fold reduction in enzyme activity and has been associated with an increased risk of breast cancer. This increased risk may be attributable to a decreased ability of the protein encoded by the low-activity allele (COMTL) to methylate and inactivate catechol estrogens, which have been implicated in estrogen carcinogenesis. Because estrogens have also been implicated in the etiology of ovarian cancer, we analyzed 108 cases and 106 controls from a case-control study conducted in Mainz, Germany, to test the hypothesis that COMTL is associated with ovarian cancer risk. No significant association was found between the COMT genotype and ovarian cancer risk (for the intermediate-activity COMT genotype versus the high-activity COMT genotype, OR, 1.29; 95% CI, 0.63-2.64; for the low-activity COMT genotype versus the high-activity COMT genotype, OR, 1.17; 95% CI, 0.52-2.61). We also hypothesized that women who were both low-activity COMT genotype- and glutathione S-transferase (CST) M1- and/or T1 null would be at higher risk for ovarian cancer because the combination of these genotypes could theoretically lead to higher catechol estrogen exposure. However, the association between the COMT polymorphism and ovarian cancer risk was similar across GSTM1 and GSTT1 genotypes (Ptrend > 0.40, for all strata). Because of the small sample size of this study population, odds ratios of a small magnitude could not be completely ruled out; however, the results presented do not support a strong association between the COMT polymorphism and the risk of ovarian cancer.

AB - A valine-108-methionine polymorphism in exon 4 of the catechol-O-methyltransferase (COMT) gene muses a 3- to 4-fold reduction in enzyme activity and has been associated with an increased risk of breast cancer. This increased risk may be attributable to a decreased ability of the protein encoded by the low-activity allele (COMTL) to methylate and inactivate catechol estrogens, which have been implicated in estrogen carcinogenesis. Because estrogens have also been implicated in the etiology of ovarian cancer, we analyzed 108 cases and 106 controls from a case-control study conducted in Mainz, Germany, to test the hypothesis that COMTL is associated with ovarian cancer risk. No significant association was found between the COMT genotype and ovarian cancer risk (for the intermediate-activity COMT genotype versus the high-activity COMT genotype, OR, 1.29; 95% CI, 0.63-2.64; for the low-activity COMT genotype versus the high-activity COMT genotype, OR, 1.17; 95% CI, 0.52-2.61). We also hypothesized that women who were both low-activity COMT genotype- and glutathione S-transferase (CST) M1- and/or T1 null would be at higher risk for ovarian cancer because the combination of these genotypes could theoretically lead to higher catechol estrogen exposure. However, the association between the COMT polymorphism and ovarian cancer risk was similar across GSTM1 and GSTT1 genotypes (Ptrend > 0.40, for all strata). Because of the small sample size of this study population, odds ratios of a small magnitude could not be completely ruled out; however, the results presented do not support a strong association between the COMT polymorphism and the risk of ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034520508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034520508&partnerID=8YFLogxK

M3 - Article

C2 - 11142424

AN - SCOPUS:0034520508

VL - 9

SP - 1373

EP - 1376

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -